- Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis
- Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine Oxidase drug discovery platform
- First Venture Investment in Public Equity (VIPE) led by Arix, taking core portfolio to 14 companies.
Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an 11 per cent interest in Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
To continue reading the press release please click here